Secondary Failure of Metformin Monotherapy in Clinical Practice by Brown, Jonathan B. et al.
Secondary Failure of Metformin
Monotherapy in Clinical Practice
JONATHAN B. BROWN, PHD, MPP
1
CHRISTOPHER CONNER, PHARMD, PHD
2
GREGORY A. NICHOLS, PHD
1
OBJECTIVE — We sought to document the secondary failure rate of metformin mono-
therapy in a clinical practice setting and to explore factors that predict therapeutic failure.
RESEARCH DESIGN AND METHODS — We studied 1,799 type 2 diabetic patients
who, between 2004 and 2006, lowered their A1C to 7% after initiating metformin mono-
therapy as their ﬁrst-ever anti-hyperglycemic drug. We examined all A1C values recorded
through31December2008(2–5yearsoffollow-up),deﬁningsecondaryfailureasasubsequent
A1C 7.5% or the addition or substitution of another anti-hyperglycemic agent. We used
logistic regression to identify factors associated with the probability of secondary failure.
RESULTS — Ofthe1,799patientsstudied,42%(n748)experiencedsecondaryfailure;the
meanfailureratewas17%peryear.However,patientswhoinitiatedmetforminwithin3months
ofdiabetesdiagnosisfailedatanage-andA1C-adjustedrateof12.2%(10.5–14.4%)peryear,and
patients who initiated while A1C was 7% failed at an adjusted rate of 12.3% per year. An
interaction term between duration of diagnosed diabetes and A1C was not signiﬁcant. Age,
duration, and A1C at initiation were the only factors that predicted secondary failure.
CONCLUSIONS — Although metformin failure may occur more rapidly in clinical practice
than in clinical trails, initiating it soon after diabetes diagnosis and while A1C is low might
preserve -cell function, prolong the effectiveness of metformin, reduce lifetime glycemic bur-
den, and prevent diabetes complications. Our ﬁndings support the current treatment algorithm
for hyperglycemia management that recommends metformin initiation when diabetes is ﬁrst
diagnosed.
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T
heDiabetesPreventionProgramand
other primary prevention studies
(1–3) have shown that metformin
therapy can slow the deterioration of gly-
cemic control in individuals with im-
paired glucose tolerance, thus delaying
progressiontodiabetes.Thissuggeststhat
initiationofmetforminassoonasdiabetes
is diagnosed would also help to slow the
trajectory of loss in insulin secretory ca-
pacity and glycemic control, delaying the
need for subsequent therapy intensiﬁca-
tion and the substantial periods of
chronichyperglycemiathattypicallyac-
company anti-hyperglycemic failure.
Therefore, the current American Diabe-
tesAssociation(ADA)andtheEuropean
Association for the Study of Diabetes
(EASD) guidelines for the medical man-
agement of type 2 diabetes recommend
the initiation of metformin concur-
rently with lifestyle intervention at di-
agnosis (4).
Observational studies indicate that
initiation of metformin or sulfonylurea
pharmacotherapy at lower levels of hy-
perglycemiaappearstoimprovetheeffec-
tivenessanddurabilityofthetherapy,but
in these studies, duration of diabetes (de-
layininitiationoftherapy)didnotpredict
time to therapy failure (5,6). However,
thesestudieswereconductedwhensulfo-
nylureas were the ﬁrst-line agent of
choice,andtheyusedanA1Ccutpointof
8%todeﬁneinitialsuccessandsecondary
treatment failure. To our knowledge, no
studies have examined the potential ben-
eﬁts of immediate versus delayed met-
formininitiationusedwithamodernA1C
treatment threshold of 7%. Furthermore,
although metformin fails at a rate of 4%
per year in clinical trials (7), the failure
rate in the real world of clinical practice
has not been reported.
We therefore sought to estimate the
rate of secondary metformin mono-
therapy experienced by unselected pa-
tients in a nonresearch setting who had a
documented history of successfully low-
ering their A1C to 7% with metformin.
We then sought to identify factors associ-
ated with slower loss of glycemic control.
Our observational analyses were con-
ducted within a managed care plan using
electronic medical records with substan-
tial information technology support, in-
cluding built-in alerts for A1C testing.
RESEARCH DESIGN AND
METHODS
Study site
Kaiser Permanente Northwest (KPNW) is
a nonproﬁt group-model HMO that pro-
vides comprehensive prepaid coverage to
470,000 members in Northwest Ore-
gon and Southwest Washington. KPNW
useselectronichealthcareutilizationdata
to track and facilitate operations. An elec-
tronic medical record, in use since 1996,
allows the attending clinician to record as
many as 20 International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁca-
tion (ICD-9-CM) coded diagnoses at each
ambulatorypatientcontactanduptonine
discharge diagnoses for inpatient hospital
admissions. An electronic problem list,
also coded in ICD-9-CM, is available to
the clinician at each contact. A single re-
gional laboratory performs nearly all
KPNW laboratory tests, and the results
are stored in a searchable database. A
pharmacy is located in each medical of-
ﬁce, and most members have a pharmacy
beneﬁt, helping to ensure complete cap-
ture of pharmaceutical dispenses.
Sample selection
Using an observational cohort design,
we identiﬁed all 3,388 type 2 diabetic
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of 250.xx) who initiated metformin
monotherapy as their ﬁrst-ever anti-
hyperglycemic drug between 1 January
2004 and 31 December 2006 and were
KPNW members for at least 1 year before
their ﬁrst metformin dispense. We ex-
cluded780patientswhoexperiencedpri-
mary failure of metformin in the ﬁrst 6
monthsoftherapy,deﬁnedas1)receiptof
only a single metformin dispense, 2) re-
ceipt of less than a 90-day supply, or 3)
addition of a second anti-hyperglycemic
agent. Because our focus was on second-
ary failure after initial success, we then
excluded 709 patients who did not attain
an A1C 7% despite ongoing therapy
and 100 patients with missing A1C data
for a ﬁnal sample of 1,799.
Secondary failure
Wedeﬁnedsecondaryfailureas1)thead-
dition or substitution of a second anti-
hyperglycemic agent or 2) a subsequent
A1C 7.5%, a level slightly above the ac-
tion level of 7.0% currently recom-
mended by the ADA and EASD (4). We
used this higher threshold to provide cer-
tainty that A1C levels had risen durably
above 7.0% and to account for recently
publishedtrialsthatreportadverseeffects
ornobeneﬁcialeffectsofglycemiccontrol
below 7.0%. We tested the sensitivity of
our results to A1C failure thresholds of
7.0 and 8.0% and also examined the two
deﬁnitions of failure (A1C 7.5% or ad-
dition/substitution of a second drug)
independently.
Analysis and covariates
We calculated age and duration of diabe-
tes using the ﬁrst metformin dispensing
date as the index date. A1C before met-
formin was the last value recorded on or
before the index date. Similarly, BMI,
bloodpressure,lipidlevels,andestimated
glomerular ﬁltration rate were based on
the last values recorded on or before the
index date. Average daily dose of the ini-
tial metformin dispensed was calculated
by summing the total number of milli-
grams dispensed and dividing by days of
supply.Theanalysisperiodforestimating
time to failure was from the date of the
ﬁrst A1C 7.0% until secondary failure
or 31 December 2008, whichever oc-
curred ﬁrst. Patients who left the health
planwerecensoredasoftheirtermination
date. To control for different patterns of
medication-taking behavior among pa-
tients, we calculated a measure of adher-
ence,themedicationpossessionratio,asa
potential covariate. Because the duration
of potential possession varied in our data
dependingontimetofailureorcensoring,
we calculated the medication possession
ratiousingperson-speciﬁcdenominators.
We estimated a logistic regression model
to assess the independent contribution of
demographic and patient characteristics,
including medication possession ratio, to
the probability of experiencing secondary
failure. All candidate predictors were en-
tered into the model simultaneously, and
those that were statistically signiﬁcant
(P  0.05) were retained in the ﬁnal
model. We used regression for incidence
densities to estimate the secondary failure
rateper1,000person-yearsbutreportthe
ﬁgures as percent per year to facilitate
comparison to published data. When
stratiﬁed by baseline A1C, the secondary
failure rates were adjusted for age, sex,
and duration of diabetes. When stratiﬁed
by duration, the rates were adjusted for
age, sex, and baseline A1C. All analyses
were performed with SAS version 8.2
(SAS Institute, Cary, NC).
RESULTS— Of the 1,799 patients
who achieved A1C 7% with the initia-
tion of metformin monotherapy as their
ﬁrst-ever anti-hyperglycemic, 42% (n 
748) experienced secondary failure (Ta-
ble 1) within the 2-to 5-year follow-up
period,arateof17.0%(15.8–18.2%)per
year. Younger age (57.7 vs. 59.2 years,
P  0.008), longer duration of diabetes
beforetherapy(26.5vs.21.4months,P
0.001), and higher A1C at metformin ini-
tiation (8.2 vs. 7.9%, P  0.001) were
associated with failure. Individuals who
failed did so within a mean of 16.9
months.Individualswhodidnotfailwere
followed for a mean of 27.6 months (P 
0.001). Of the 748 patients who experi-
enced secondary failure, 70% reached an
A1C 7.5, and 30% added a second
drug,mostofwhomdidsowhilecontinu-
ing metformin (data not shown).
As displayed in Table 2, we observed
considerable variation in the time be-
tween diabetes diagnosis and the start of
metformin: 40% of patients who initiated
metformin did so within 3 months of di-
agnosis, but 25% waited 36 or months or
longer. Failure was less likely among in-
dividuals who started metformin sooner
(P value for 
2 of distribution 0.001).
A1C at metformin initiation also varied,
with 27% initiating while A1C was 7
and 23% initiating while A1C was
9.0%. Failure was slower among indi-
vidualswhostartedmetforminwhenA1C
Table 1—Characteristics of patients who did and did not experience secondary failure of
metformin monotherapy after achieving A1C <7%
Failed metformin
Did not fail
metformin P
n (%) 748 (41.6) 1,051 (58.4) —
Age at initiation 57.7  12.3 59.2  11.3 0.008
Diabetes duration (months) 26.5  29.6) 21.4  28.0 0.001
Last metformin dose 1,465  564 1,342  573 0.001
A1C before metformin (%) 8.2  1.8 7.9%  1.8 0.001
% Male 50.0 47.3 0.257
% Non-white 10.0 10.2 0.904
Initial metformin dose (mg) 1,073  502 1,076  508 0.903
BMI (kg/m
2) 35.7  7.7 35.6  8.0 0.842
Systolic blood pressure (mmHg) 134  13 135  14 0.129
Diastolic blood pressure (mmHg) 79  87 9  9 0.823
LDL cholesterol (mg/dl) 111  36 113  34 0.319
HDL cholesterol (mg/dl) 42  10 41  11 0.443
Triglycerides (mg/dl) 256  269 241  244 0.255
Estimated glomerular ﬁltration
rate (ml/min) 93  25 92  26 0.262
% With cardiovascular disease 13.5 14.5 0.564
% With nephropathy 0.4 0.8 0.309
% With retinopathy 0.4 0.1 0.222
% with neuropathy 5.1 2.9 0.020
Medicine possession ratio 0.8 71.5 66.7 0.030
Months to failure or end 16.9  12.2 27.6  13.3 0.001
Data are means  SD or percent, unless otherwise indicated.
Secondary failure of metformin monotherapy
502 DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 care.diabetesjournals.orgwas lower (P value for 
2 of distribution
0.001).
In the multivariable analysis, only
three of the 20 patient characteristics de-
scribed in Table 1 were independent pre-
dictors of the odds of secondary failure of
metformin monotherapy: younger age,
time between diagnosis and therapy, and
A1C before therapy initiation. Compared
with patients who initiated metformin
within 3 months of diabetes diagnosis,
those who initiated in 4–11 months were
56% more likely to experience secondary
failure (odds ratio 1.56, 95% CI 1.12–
2.18), and patients who initiated 36 or
more months after diagnosis were more
than twice as likely to fail (2.20, 1.68–
2.87). Similarly, patients with A1C at
metformininitiationof7–7.9,8–8.9,and
9.0% were 53% (1.53, 1.19–1.98),
73% (1.73, 1.27–2.35), and 104% (2.04,
1.54–2.72)morelikelytoexperiencesec-
ondary failure, respectively, relative to
those with A1C 7.0%. However, these
effects were independent: an interaction
term linking duration of diabetes to A1C
wasnotsigniﬁcant.Themultivariablesta-
tistical model had modest discrimination
(c statistic  0.613) and adequate ﬁt
(Hosmer-Lemeshow 
2  8.3, P 
0.405).
Expressed as a rate, after adjustment
for age and A1C before therapy, met-
formin failed in 12.2% (10.5–14.4%) of
patientswhoinitiatedmetforminwithin3
months of diabetes diagnosis each year,
compared with 17.8–21.9% of other pa-
tients (Fig. 1). Patients who started met-
formin while A1C was 7% failed at an
age-and duration-adjusted rate of 12.3%
per year, compared with 17.8–19.4% in
other A1C categories (Fig. 2).
Table2—DistributionofdiabetesdurationandA1Catmetformininitiationandparsimonious
logistic regression of the probability of secondary failure of metformin
Failed
metformin
(n  748)
Did not fail
metformin
(n  1,051)
Odds
ratio 95% CI P
Mean age* 57.7 (12.3) 59.2 (11.3) 0.98 0.97–0.99 0.001
Duration of diabetes
(months)†
0–3 34.2% 44.4% 1.00 — —
4–11 11.0% 11.0% 1.56 1.12–2.18 0.008
12–23 14.8% 11.6% 2.09 1.53–2.87 0.001
24–35 10.7% 10.7% 1.59 1.13–2.24 0.007
36 29.3% 22.3% 2.2 1.68–2.87 0.001
A1C (%)†
7.0 20.5% 30.9% 1.00 — —
7.0–7.9 35.8% 33.3% 1.53 1.19–1.98 0.001
8.0–8.9 17.9% 14.9% 1.73 1.27–2.35 0.001
9.0 25.8% 20.8% 2.04 1.54–2.72 0.001
Hosmer-Lemeshow 
2 8.3 0.405
c Statistic 0.613
*P  0.008. †
2 for distribution P  0.001.
Figure 1—Kaplan-Meier plot of secondary failure of metformin monotherapy by categories of duration of diabetes at metformin initiation adjusted
for age and A1C at initiation and the percent per year (95% CIs) experiencing secondary failure.
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tional cohort study of 1,799 patients who
lowered their A1C to below 7% using
metformin monotherapy as their ﬁrst-
ever anti-hyperglycemic agent, we found
thatinitiatingmetforminwithin3months
of diabetes diagnosis was associated with
a substantial reduction in the odds of sec-
ondary loss of glycemic control. This re-
sult is consistent with the hypothesis that
early initiation of metformin preserves
-cell function and supports the current
ADA/EASD hyperglycemia treatment al-
gorithm (4), which recommends met-
formin therapy as soon as type 2 diabetes
is diagnosed. We also found that lower
A1C at treatment initiation was indepen-
dently associated with a reduced risk of
secondary failure. Importantly, only sub-
jects with the shortest diabetes duration
(0–3 months) and the lowest baseline
A1C (7%) beneﬁted; overlapping con-
ﬁdence intervals among the other catego-
ries of duration and A1C suggested no
difference in the probability of failure.
Of metformin initiators, 42% experi-
enced secondary failure within a mean
follow-up period of 27.6 months (2 years
and 2 months). This equates to an annual
failure rate of 17%, substantially greater
than the 4% per year reported in ADOPT
(A Diabetes Outcome Progression Trial)
(7). ADOPT deﬁned failure as fasting
plasma glucose 180 mg/dl, a level that
correlates to an A1C of 8% (8), whereas
we used an A1C cut point of 7.5%. We
also included the addition or substitution
ofotheranti-hyperglycemicagentswithin
our deﬁnition of failure. Metformin
monotherapy might therefore be less du-
rable than the experience of highly
screened volunteers treated by research
physicians would suggest. Discrepancies
between real-world “effectiveness” stud-
ies and trials of clinical efﬁcacy are not
uncommon (9). In addition, our results
are consistent with one prior observa-
tional study of untreated patients with
A1C 7.0% that similarly found that
lowerbaselineA1Candyoungeragewere
the major independent predictors of pro-
gression (A1C 7% or initiation of ther-
apy) (10). We also note that sensitivity
analyses examining the two deﬁnitions of
failure independently, and alternative
A1C thresholds of 7 and 8%, did not
change our results.
Long-termobservationalfollow-upof
theUKProspectiveDiabetesStudycohort
showed that intensively treated patients
maintained lower risks for any diabetes-
related end point, microvascular disease,
myocardial infarction, and all-cause mor-
tality well after between-group differ-
ences in glycemic control disappeared
(11). The UK Prospective Diabetes Study
observations support the hypothesis that
early control of hyperglycemia creates a
beneﬁcial“legacyeffect”incardiovascular
disease prevention. A recent joint state-
mentoftrialistsandscientiﬁcassociations
further supports this point of view (12).
The association between immediate met-
formin initiation and preservation of gly-
cemic control that we now report might
therefore have signiﬁcant health and eco-
nomic beneﬁts.
In our data, the importance of early
initiation of metformin applied to the
full range of patients with recently
diagnosed type 2 diabetes. Presence of
microvascular and macrovascular comor-
biditiesdidnotaffectthisﬁnding,nordid
other predictors including A1C at initia-
tion, BMI, blood pressure, lipids, adher-
ence, or estimated glomerular ﬁltration
rate. However, it is important to note that
our results are limited to the subset of
metformin initiators who succeeded in
loweringtheirA1Cto7%.Weweresur-
Figure 2—Kaplan-Meier plot of secondary failure of metformin monotherapy by categories of A1C at metformin initiation adjusted for age and
diabetes duration at initiation and the percent per year (95% CIs) experiencing secondary failure.
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only 53% of the 3,388 patients who
initiated metformin monotherapy as their
ﬁrst-ever anti-hyperglycemic drug. Al-
though metformin is reported to be well
tolerated and effective (13,14), in our
sample,780(23%)patientseitherdidnot
reﬁlltheirinitialdispense,reﬁlledsporad-
ically, or added or switched to a second
agent within 6 months of metformin ini-
tiation.Another709patientswereunable
to reduce their A1C to below 7%. Clini-
cians wishing to optimize their patients’
glycemic control should recognize that
metformin may be less tolerable, less ef-
fective, and less durable than is com-
monly believed and be prepared to
respond to failure quickly.
Our results show an association be-
tween earlier use of metformin and
lengthened effectiveness of the drug, pos-
siblyresultingfrommoreeffectivepreser-
vation of -cell function. Therapeutic
effectiveness requires therapeutic adher-
ence, but adherence was not an indepen-
dent predictor of success in our data,
probably because it was relatively high
among all patients. This is likely due to
the study design, which limited the study
sample to patients who had initially suc-
ceeded with metformin therapy. In fact,
in univariate analysis, adherence (medi-
cationpossessionratio80%)wassome-
what greater among patients who
subsequently failed metformin. This is
consistent with a previous study in which
patients with the highest adherence had
greater odds of therapy intensiﬁcation af-
ter an elevated A1C (15).
Our ﬁndings must be interpreted
with caution for two reasons. First, pa-
tientswhoinitiatedmetforminwhileA1C
was lower likely achieved the lowest A1C
levels.Ifso,itwouldbeexpectedthatthey
would be able to remain below 7.5% for
longer periods. However, all patients
achieved an A1C below 7%. Second, pa-
tientswithlongerdurationofdiabetesbe-
fore metformin initiation may have been
ingoodcontrolformuchofthatuntreated
period, in which case their total time in
control before metformin failure could
have actually been greater than patients
who initiated metformin immediately.
Our objective was to assess the success of
metformin therapy in drug-naïve patients
and to identify predictors of metformin
durability. Thus, we chose to evaluate
only treated time in our analyses.
As an observational analysis, our
study has some inherent limitations. Our
results could be affected by measurement
of A1C levels at irregular intervals and
frequencies. We could not observe
whether patients who added another
agent before an elevated A1C did so be-
cause of metformin’s known gastroin-
testinal side effects or whether their
doctors were more aggressive propo-
nentsoftightglycemiccontrol.Further-
more, the organizational structure of
KPNW and the existence of an elec-
tronic medical record with substantial
information technology support, in-
cluding built-in alerts for A1C testing,
may limit the generalizability of our
study to other real-world settings.
Diabetes is a progressive disease that
typicallyrequiresongoingtherapeuticad-
justments to maintain glycemic control
(16). As therapies lose their effectiveness,
long delays frequently result in substan-
tial glycemic burden that accumulates
over time (17). Our study suggests that
initiating metformin soon after diabetes
diagnosis and while A1C is low may im-
prove the durability of metformin,
thereby delaying the need for therapeutic
adjustments and reducing the glycemic
burdenassociatedwithitsfailure.Further
research should focus on whether earlier
metformin monotherapy reduces the risk
of microvascular and macrovascular
complications.
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